View Older Stories View More Recent Stories
-
PTC Therapeutics (PTCT) Provides Regulatory Update on Translarna in Europe
-
PTC Therapeutics (PTCT) Presents New Sepiapterin Data from Ongoing Studies
-
BofA Securities Upgrades PTC Therapeutics (PTCT) to Neutral
-
Scotiabank Starts PTC Therapeutics (PTCT) at Sector Perform
-
Cantor Fitzgerald Reiterates Overweight Rating on PTC Therapeutics (PTCT)
-
PTC Therapeutics (PTCT) Misses Q4 EPS by 6c
-
PTC Therapeutics (PTCT) PT Raised to $60 at TD Cowen Following FDA Acceptance and Priority Review for Vatiquinone NDA
-
PTC Therapeutics (PTCT) Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia
-
PTC Therapeutics (PTCT) PT Raised to $113 at Cantor Fitzgerald
-
PTC Therapeutics (PTCT) PT Raised to $50 at TD Cowen
-
RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
-
PTC Therapeutics (PTCT) Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference
-
TD Cowen: '10 Potential "Thome Run" Catalysts to Watch in 2025'
-
PTC Therapeutics (PTCT) Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia
-
Morgan Stanley Upgrades PTC Therapeutics (PTCT) to Overweight
-
PTC Therapeutics (PTCT) spreader of 2186 contracts of January 35 and January 45 puts
-
PTC Therapeutics (PTCT) PT Raised to $32 at Citi
-
PTC Therapeutics (PTCT) PT Raised to $42 at Goldman Sachs
-
PTC Therapeutics (PTCT) PT Raised to $70 at Baird
-
JPMorgan Reiterates Overweight Rating on PTC Therapeutics (PTCT)
-
RBC Capital Upgrades PTC Therapeutics (PTCT) to Outperform, 'NVS HD Deal Meaningfully Improves Fundamentals'
-
PTC Therapeutics (PTCT) Enters into a Global License and Collaboration Agreement with Novartis (NVS) for PTC518 Huntington's Disease Program
-
JPMorgan is out with its 2025 outlook for biotech stocks
-
PTC Therapeutics (PTCT) PT Raised to $52 at Baird
-
PTC Therapeutics (PTCT) to Sell Priority Review Voucher for $150M
-
PTC Therapeutics (PTCT) all put ratio 11.7 calls to 1 put into quarter results
-
After-hours movers: HP Inc., Dell Technologies, Workday and more
-
PTC Therapeutics (PTCT) Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients
-
PTC Therapeutics (PTCT) Tops Q3 EPS by 12c, provides guidance
-
PTC Therapeutics (PTCT) Announces FDA Acceptance of Translarna NDA Resubmission
-
PTC Therapeutics (PTCT) Reports CHMP Maintained Negative Opinion on Translarna Reexamination
-
Citi Reiterates Sell Rating on PTC Therapeutics (PTCT)
-
PTC Therapeutics (PTCT) Announces FDA Target Regulatory Action Date of July 29, 2025 for Sepiapterin and Lancet Publication of Phase 3 Trial Results
-
Raymond James Resumes PTC Therapeutics (PTCT) at Market Perform
-
Baird Reiterates Outperform Rating on PTC Therapeutics (PTCT)
-
Goldman Sachs Reiterates Sell Rating on PTC Therapeutics (PTCT)
-
TD Cowen Reiterates Hold Rating on PTC Therapeutics (PTCT)
-
PTC Therapeutics (PTCT) Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program
-
PTC Therapeutics (PTCT) Announces FDA Acceptance for Filing of NDA for Sepiapterin
-
Baird Reiterates Outperform Rating on PTC Therapeutics (PTCT)
-
PTC Therapeutics (PTCT): FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program
-
TD Cowen Reiterates Hold Rating on PTC Therapeutics (PTCT)
-
Baird Starts PTC Therapeutics (PTCT) at Outperform
-
PTC Therapeutics (PTCT) ATM March 34 calls active
-
PTC Therapeutics (PTCT) PT Raised to $33 at TD Cowen
-
PTC Therapeutics (PTCT) Submits Sepiapterin NDA Submission to FDA
-
PTC Therapeutics (PTCT) Receives Negative CHMP Opinion on Translarna
-
PTC Therapeutics (PTCT) PT Raised to $32 at BofA Securities
-
Goldman Sachs Reiterates Sell Rating on PTC Therapeutics (PTCT)
-
JPMorgan on PTC Therapeutics (PTCT): 'Despite Notable Unknowns for Clinical & Regulatory Outlook, 12-mo PIVOT-HD Update Solidly Encouraging on All Fronts'
